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To explore the parmacokinetics, safety and tolerability of paclitaxel after oral administration of SMEOF#3, a novel Self-
Microemulsifying Oily Formulation, in combination with cyclosporin A (CsA) in patients with advanced cancer. Seven patients were
enrolled and randomly assigned to receive oral paclitaxel (SMEOF#3) 160mgþCsA 700mg on day 1, followed by oral paclitaxel
(Taxol
s) 160mgþCsA 700mg on day 8 (group I) or vice versa (group II). Patients received paclitaxel (Taxol
s) 160mg as 3-h
infusion on day 15. The median (range) area under the plasma concentration–time curve of paclitaxel was 2.06 (1.15–
3.47)mghml
 1 and 1.97 (0.58–3.22)mghml
 1 after oral administration of SMEOF#3 and Taxol
s, respectively, and 4.69 (3.90–
6.09)mghml
 1 after intravenous Taxol
s. Oral SMEOF#3 resulted in a lower median Tmax of 2.0 (0.5–2.0)h than orally applied
Taxol
s (Tmax¼4.0 (0.8–6.1)h, P¼0.02). The median apparent bioavailability of paclitaxel was 40 (19–83)% and 55 (9–70)% for
the oral SMEOF#3 and oral Taxol
s formulation, respectively. Oral paclitaxel administered as SMEOF#3 or Taxol
s was safe and well
tolerated by the patients. Remarkably, the SMEOF#3 formulation resulted in a significantly lower Tmax than orally applied Taxol
s,
probably due to the excipients in the SMEOF#3 formulation resulting in a higher absorption rate of paclitaxel.
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Currently, paclitaxel is only marketed as an intravenous (i.v.)
formulation. Paclitaxel is poorly soluble in most pharmaceutical
solvents, therefore, in the marketed i.v. formulation it is
formulated in a 1:1 combination of the solubilising agent
polyoxyethylated caster oil (Cremophor
s EL (CrEL)) and dehy-
drated ethanol. CrEL has been reported to be responsible for
severe hypersensitivity reactions (Webster et al, 1997) and the
nonlinear pharmacokinetic behaviour of i.v. administered pacli-
taxel (Sparreboom et al, 1996; van Tellingen et al, 1999; van Zuylen
et al, 2001a).
Oral administration of paclitaxel might be attractive because it is
more convenient for patients than i.v. administration. Further-
more, oral paclitaxel administration may enable the development
of treatment regimens resulting in plasma concentrations above a
pharmacologically relevant level for more prolonged periods of
time. However, oral treatment with paclitaxel is severely hampered
because of its low bioavailability, which is caused by two main
reasons. Firstly, paclitaxel is a high-affinity substrate for the efflux
multidrug transporter P-glycoprotein (P-gp), which is highly
expressed in the gastrointestinal tract (Sparreboom et al, 1997).
Secondly, paclitaxel undergoes first-pass metabolism by the gut
and liver cytochrome P450 (CYP) enzymes (CYP 2C8 and CYP
3A4).
Previous studies carried out at our Institute investigated the
pharmacokinetics of the i.v. paclitaxel formulation after oral
administration as a drinking solution diluted with water (Meerum
Terwogt et al, 1999; Malingre ´ et al, 2000a,b; Malingre ´ et al,
2001a–e) and revealed that coadministration of oral CsA resulted
in an increased systemic exposure to oral paclitaxel (van Asperen
et al, 1998; Meerum Terwogt et al, 1999). As CsA is an inhibitor of
both P-gp and CYP3A4, both an increased absorption and a
reduced first-pass effect may be responsible for the increased
systemic exposure. We have shown previously that systemic
exposure to paclitaxel did not increase with CsA doses higher than
10mgkg
 1 (Malingre ´ et al, 2001a–e).
Although CrEL was reported to exhibit no oral absorption
(Malingre ´ et al, 2001a–e) it affects paclitaxel pharmacokinetics by
limiting the absorption of paclitaxel from the intestine after oral
administration, probably by entrapment of paclitaxel in micelles,
thereby reducing the availability of paclitaxel for uptake (Sparre-
boom et al, 1996; Sparreboom et al, 1999; Malingre ´ et al, 2001a–e;
van Zuylen et al, 2001b; Bardelmeijer et al, 2002). Thus far, a
favourable oral formulation with paclitaxel has not been found yet.
Self-Microemulsifying Oily Formulation (SMEOF)#3 is a novel
oral SMEOF of paclitaxel. The formulation consists of an isotropic
mixture of oils and surfactants, which solubilise paclitaxel and
spontaneously forms a microemulsion upon contact with water.
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sPrevious in vivo studies in wild-type mice and mdr1a/b ( / )
knockout mice, which lack functional P-gp activity, showed that
SMEOF#3 was a suitable delivery vehicle for oral administration of
paclitaxel in combination with oral CsA (data on file). The choice
of the excipients was motivated by a previous study exploring
particle size, physical and chemical stability as well as cytotoxic
activity in vitro of different formulations of paclitaxel (Gursoy
et al, 2003). Furthermore, the physical stability was assessed of
emulsions of different SMEOFs of paclitaxel after dilution in
simulated gastric fluid (SGF). It was shown that after dilution of
the i.v. paclitaxel (Taxol
s) formulation in SGF, major part of the
micelles was destabilised and a massive precipitation immediately
occurred (data on file). This phenomenon was thought to be due to
diffusion of ethanol in the SGF after which the remaining CrEL was
not capable to maintain all paclitaxel in solution. SMEOF#3,
however, showed a good stability for about 6h after dilution in
SGF. In SMEOF#3, tyloxapol and TPGS (d-alpha-tocopheryl
polyethylene glycol 1000 succinate) have been selected for their
ability to solubilise paclitaxel. Tyloxapol is a nonionic surfactant
used in the product Exosurf
s (GlaxoSmithKline, UK). Upon
contact with water, tyloxapol was shown to form lyotropic liquid
crystals, which are are thought to contribute to the formation of
microemulsions (Gershanik and Benita, 2000). Furthermore, it was
shown that tyloxapol can be used as a cosolvent by increasing the
solubility of paclitaxel in ethanol (Gursoy et al, 2003). TPGS is a
derivative of vitamin E with amphiphillic properties and it is used
as excipient in Agenerase
s (amprenavir, GlaxoSmithKline, UK).
TPGS has been shown to increase the bioavailability of poorly
absorbed lipophilic drugs (Chang et al, 1996), probably by
its solubilising effect through improved micelle formation
(Boudreaux et al, 1993). As compared to the commercial paclitaxel
(Taxol
s) formulation tested orally, the main advantages of
SMEOF#3 are the absence of CrEL and the significantly lower
ethanol/paclitaxel ratio, which allows reducing the amount of
ethanol to be administered.
The purpose of this study was to investigate the pharmaco-
kinetics, safety and tolerability of this novel oral formulation of
paclitaxel (SMEOF#3).
PATIENTS AND METHODS
Patient population
Patients with a histological or cytological diagnosis of advanced
nonhaematological cancer for whom no curative therapy existed
and for whom treatment with single agent paclitaxel was
considered of potential benefit were eligible for the study. Patients
had to be recovered from any toxicities of prior treatment.
Previous chemotherapy was allowed as long as the last treatment
was at least 4 weeks prior to study entry and at least 3 weeks
should have elapsed since receiving radiotherapy.
Patients had to have acceptable haematological parameters
(white blood cells (WBC) X3.0 10
9l
 1, and platelets
X100 10
9l
 1)), hepatic function (serum bilirubin p20mmoll
 1;
AST and ALTp1.5 upper limit of normal (ULN) or p3 ULN
in case of liver metastases) and renal function (serum creatinine
p160mmoll
 1 or creatinine clearance X50mlmin
 1 as calculated
by Cockcroft Gault formula), and a World Health Organization
(WHO) performance status (PS) p2. Patients were excluded if
they had experienced severe toxicities on prior taxane treatment,
suffered from uncontrolled infectious disease, heart disease, bowel
obstruction or motility disorders that could have influenced the
resorption of drugs. Further exclusion criteria were concomitant
use of known P-gp and CYP 3A modulating drugs and chronic use
of H2-receptor antagonists or proton pump inhibitors. Female
patients were excluded when breast-feeding or pregnant (con-
firmed by a pregnancy test before study entry). Patients had to be
willing and able to follow the protocol requirements. The Medical
Ethics Committee of the Institute approved the study protocol and
all patients gave written informed consent.
Study design
Initially six patients were planned to be enrolled in the study and
were randomly assigned to two groups of treatment. Group I
received a combination of oral paclitaxel (SMEOF#3) 160mg and
CsA 700mg on day 1, followed by oral paclitaxel (Taxol
s) 160mg
in combination with CsA 700mg on day 8, and group II received
oral paclitaxel (Taxol
s) 160mg in combination with CsA 700mg
on day 1, followed by oral paclitaxel (SMEOF#3) 160mg and CsA
700mg on day 8. CsA was administered orally at a fixed dose of
700mg (approximately equivalent to 10mgkg
 1 CsA) 30min prior
to oral administration of paclitaxel. The patients in both groups
received a single i.v. administration of paclitaxel (Taxol
s) 160mg
as a 3-h infusion on day 15.
Drug composition and administration
The composition of SMEOF#3 (Novagali Pharma SA, Evry cedex,
France) is presented in Table 1. SMEOF#3 (160mg in 10ml) was
administered orally to the patients via a syringe within 30min after
1:3 dilution with tap water to 40ml resulting in a final paclitaxel
concentration of 4mgml
 1. The commercially available i.v.
paclitaxel (Taxol
s) formulation (Bristol-Myers Squibb, Syracuse,
NY, USA) containing paclitaxel 6mgml
 1, ethanol 396mgml
 1,
and CrEL 527mgml
 1 was administered orally after dilution of
26.7ml (160mg) with water to 40ml (4mgml
 1). The i.v. paclitaxel
(Taxol
s) formulation was administered i.v. at a fixed dose of
160mg as 3-h infusion to all patients on day 15. CsA was
administered as seven capsules of 100mg each (Neoral
s, Novartis,
Basel, Switzerland).
To prevent possible nausea and vomiting during both the
treatment with oral SMEOF#3 and oral Taxol
s, patients were
premedicated with oral granisetron (Kytril
s) 1mg approximately
2h before the intake of paclitaxel. In addition, patients received a
light standard breakfast (two crackers and a cup of tea) at least 2h
prior to each paclitaxel administration. Intake of food was not
allowed until 2h following the intake of oral paclitaxel. Patients
were premedicated with dexamethasone 20mg p.o. 8–10h prior
to, and ranitidine 50mg i.v., clemastine 2mg i.v. and dexametha-
sone 20mg i.v., 30–60min before i.v. paclitaxel dosing, to prevent
infusion-related hypersensitivity reactions. If considered in their
best interest, patients continued on a 3-weekly schedule of i.v.
paclitaxel at a dose of 175mgm
 2.
Sample collection and analysis
Blood samples for pharmacokinetic analysis of paclitaxel were
collected via an indwelling catheter in 5ml heparinised tubes after
both p.o. and i.v. administration. Following oral administration
samples were obtained prior to administration, immediately after
administration, and 15, 30, 45min, and 1, 2, 4, 6, 8, 24, 48, and 72h
after paclitaxel administration. Following i.v. administration
Table 1 Composition of SMEOF#3
Component % (wv
 1) Function
Paclitaxel 1.6 Active substance
Vitamin E 5 Oil
TPGS
a 30 Surfactant, cosolvent
Tyloxapol 30 Surfactant, cosolvent
Ethanol (anhydrous) 33.38 Solvent
Citric acid (anhydrous) 0.02 pH adjuster
Total 100
aD alpha-tocopheryl polyethylene glycol 1000 succinate.
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ssamples were obtained prior to administration, 60, 120, and
165min after start of infusion, at the end of infusion, and 15, 30,
45min, and 1, 2, 4, 6, 8, 24, 48, and 72h after infusion. Blood
samples were centrifuged, and plasma was separated and
immediately transferred into polypropylene tubes and stored at
 201C until analysis. Paclitaxel concentrations in plasma were
determined using a validated high performance liquid chromato-
graphic (HPLC) tandem mass spectrometric (MS/MS) method
(Vainchtein et al, 2006).
For the pharmacokinetic analysis of CsA, blood samples were
collected in 5ml EDTA tubes at the same time points as for
paclitaxel after the oral SMEOF#3 and oral Taxol
s administra-
tions. Whole blood samples were stored at 41C until analysis
using a specific fluorescence polarisation immunoassay (FPIA)
(Malingre ´, 2001).
Urine samples were collected prior to paclitaxel administration
and at the intervals: 0–24, 24–48, and 48–72h after oral SMEOF#3
and oral Taxol
s and after i.v. Taxol
s administration. A volume of
19ml of each urine sample was mixed with 1ml of a mixture of
5% CrEL (Sigma, Prague, Czech Republic) – ethanol (Merck,
Darmstadt, Germany) 1:1 vv
 1 to prevent paclitaxel precipitation.
Subsequently, 5ml was transferred into a 10ml polypropylene tube
and stored at  201C until analysis. Paclitaxel concentrations in
urine were determined using a validated HPLC method with
ultraviolet (UV) detection (Huizing et al, 1995).
Pharmacokinetics
The pharmacokinetic parameters of paclitaxel and CsA were
determined by noncompartmental analysis, using WinNonLint
(version 5.0, Pharsight Corporation, Mountain View, CA, USA).
The area under the plasma concentration time curve (AUC) was
determined using the linear logarithmic trapezoidal method up to
the last measured concentration-time point and extrapolated to
infinity (AUC0 N) using the slope of the terminal part of the
logarithmic concentration vs time curve (lz). Furthermore, the
terminal half-life (t1/2) was determined. The maximal observed
drug concentration (Cmax) and time to maximal observed drug
concentration (Tmax) were obtained directly from the experimental
data.
The apparent bioavailability (F) of paclitaxel was calculated by
the ratio of the AUC0 N after oral administration and AUC0 N
after i.v. administration of paclitaxel. Furthermore, the fraction of
the paclitaxel dose that was excreted unchanged in urine was
calculated.
Statistics
The software package Statistical Product and Service Solutions
(version 12.1. 1 for Windows, SPSS Inc., Chicago, IL, USA) was
used for statistical analysis. The priori level of significance was
P¼0.05. The paired t-test was applied on logarithmic-transformed
values to make a comparison between the pharmacokinetic
parameters of paclitaxel after the different study treatments.
Safety
All toxicities observed were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) version 3.0, 2003 (http://ctep.cancer.gov/
forms/CTCAEv3.pdf).
RESULTS
Patient characteristics
As one patient was not fully evaluable for pharmacokinetic
analysis, one additional patient was included and in total seven
patients were entered into the study. Patient characteristics are
specified in Table 2. Patients 1, 4, 5, and 7 were assigned to group I
and patients 2, 3, and 6 were assigned to group II. Four patients
and three patients had a PS of 1 and 2, respectively. Age, height,
and weight appeared to be equally distributed over the two
treatment groups.
Drug administration and extent of exposure
All patients received all three treatments (day 1, 8, and 15) at the
single flat dose of 160mg per formulation. The i.v. administration
of Taxol
s during day 15 was temporally interrupted in patient 1
due to infusion leakage. Patient 4, a 54 years old female, developed
rash and dyspnoea 15min following i.v. paclitaxel administration.
The paclitaxel infusion was terminated and 2mg clemastine i.v.
was given, which resolved the hypersensitivity reaction. Therefore,
blood sampling for pharmacokinetics could not be performed and
this patient was not fully eligible. Intravenous paclitaxel admin-
istration was restarted after one hour at a lower infusion rate,
which did not cause any adverse reactions.
Pharmacokinetic and statistical analysis
Figure 1 depicts the plasma pharmacokinetic profiles of paclitaxel
after treatment with p.o. paclitaxel (SMEOF#3), p.o. paclitaxel
(Taxol
s)( n¼7), and i.v. paclitaxel (Taxol
s) 160mg as 3h
infusion (n¼6). Interpatient variability in paclitaxel plasma
concentrations was comparable between p.o. SMEOF#3 and
Table 2 Patient characteristics
No. of patients 7
Male/female 5/2
Median age, years (range) 56 (29–63)
Median PS (range) 1 (1–2)
Tumour type
NSCL 1
Stomach 1
Neuroendocrinal 1
Thyroid 1
Oesophagus cardia 2
Parotid gland 1
Prior treatment
Surgical therapy 5
Chemotherapy 7
Radiotherapy 4
1
p.o. SMEOF#3+CsA
p.o. Taxol

+CsA
i.v. Taxol

0.1
0.01
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Figure 1 Paclitaxel plasma concentration vs time curves after p.o.
SMEOF#3 160mgþCsA 700mg, p.o. Taxol
s 160mgþCsA 700mg
(n¼7), and i.v. Taxol
s 160mg as 3h infusion (n¼6). Data are
represented as mean7s.d. on a semi-logarithmic scale.
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sp.o. Taxol
s, both coadministered with CsA, but was lower after i.v.
administered Taxol
s.
Figure 2 presents the AUC0 N (mghml
 1), Cmax (mgml
 1), and
Tmax (h) of paclitaxel after p.o. SMEOF#3, p.o. Taxol
s and after i.v.
Taxol
s given as 3h infusion. Tmax after oral SMEOF#3 was sub-
stantially lower compared to p.o. paclitaxel (Taxol
s)( P¼0.021).
The plasma pharmacokinetic parameters of paclitaxel after
the three study treatments are depicted in Table 3. The median
(range) AUC0 N of the SMEOF#3 formulation was 2.06 (1.15–
3.47)mghml
 1, which was not significantly higher than the
AUC0 N of 1.97 (0.58–3.22)mghml
 1 after oral Taxol
s
(P¼0.74). The interpatient variability in AUC0 N was relatively
high after both p.o. SMEOF#3 (%CV¼42) and p.o. Taxol
s
(%CV¼45). Furthermore, oral SMEOF#3 resulted in a not
significantly higher median Cmax of 0.21 (0.15–0.35)mgml
 1
compared to a Cmax of 0.16 (0.10–0.29)mgml
 1 after oral Taxol
s
(P¼0.15). Remarkably, oral SMEOF#3 showed a significantly
lower Tmax of 2.0 (0.5–2.0)h than p.o. Taxol
s, which had a Tmax of
4.0 (0.8–6.1)h (P¼0.021). The median apparent bioavailability
was 40% (19–83%) and 55% (9–70%) for the oral SMEOF#3 and
oral Taxol
s formulation, respectively. After both i.v. and oral
administration excretion of paclitaxel in the urine was low and
more than 70% of the total urinary excretion occurred within 24h.
Figure 3 depicts the mean pharmacokinetic profiles of CsA after
oral administration of CsA 700mg in combination with p.o.
SMEOF3# 160mg and p.o. Taxol
s 160mg (n¼7). The pharma-
cokinetic parameters of CsA of all three study treatments are
summarised in Table 4.
Figure 3 and Table 4 clearly show that CsA pharmacokinetics
were not influenced by coadministration of either paclitaxel
formulations.
Safety evaluation
Nonhaematological toxicities were CTCAE grade 1–2, except for
two grade 3 events: one hypersensitivity reaction in patient 4 after
i.v. paclitaxel administration, and muscular weakness in patient 1,
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Figure 2 Individual AUC0 N, Cmax, and Tmax values of paclitaxel after
treatment with p.o. SMEOF#3 and p.o. Taxol
s (n¼7), both coadminis-
tered with CsA, and after treatment with i.v. Taxol
s (n¼6).
Table 3 Plasma pharmacokinetic parameters of paclitaxel after p.o.
SMEOF#3 160mg, p.o. Taxol
s 160mg (n¼7), and i.v. Taxol
s 160mg as
3h infusion (n¼6)
Parameter SMEOF#3 p.o. Taxol
s p.o. Taxol
s i.v.
Tmax (h) 2.0 (0.5–2.0) 4.0 (0.8–6.1) NA
Cmax (mgml
 1) 0.21 (0.15–0.35) 0.16 (0.10–0.29) 1.05 (0.77–0.15)
AUC0-N (mghml
 1) 2.06 (1.15–3.47) 1.97 (0.58–3.22) 4.69 (3.90–6.09)
%CV of AUC 42 45 18
t1/2 (h) 23 (20–28) 22 (17–33) 23 (16–32)
F(%) 40 (19–83) 55 (9–70)
%CV of F 59 48
Uexcr (% of dose)
a 1.3 (0.5–2.1) 1.7 (0.6–3.6) 5.0 (3.4–8.3)
Data are presented as median (range). NA, not applicable.
aUexcr, urinary paclitaxel
excretion. %CV % coefficient of variation.
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Figure 3 CsA blood concentration vs time curves after administration of
CsA 700mg in combination with oral SMEOF#3 and oral Taxol
s (n¼7).
Data are represented as mean7s.d. on a semi-logarithmic scale.
Table 4 Plasma pharmacokinetic parameters of CsA after administration
of CsA 700mg in combination with p.o. SMEOF#3 160mg and p.o.
Taxol
s 160mg (n¼7)
Parameter SMEOF#3 Taxol
s
Tmax (h) 2.6 (0.8–2.8) 1.5 (0.8–6.7)
Cmax (mgml
 1) 1.48 (0.86–2.89) 1.51 (0.80–2.71)
AUC0-N (mghml
 1) 13.3 (10–23.8) 15.8 (8.95–25.1)
%CV of AUC 32 34
t1/2 (h) 17 (12–28) 20 (8–34)
Data are presented as median (range).
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sthat was considered to be probably related to SMEOF#3. No life
threatening adverse events (grade 4) and deaths (grade 5) were
reported in the study. Overall, the most frequently reported drug-
related adverse events were gastrointestinal disorders with the
most common symptoms of nausea occurring in three patients
after oral administration of paclitaxel. Furthermore, abdominal
pain, diarrhoea, and stomatitis were reported in two patients. No
clinical relevant haematological toxicities occurred after the three
treatments. Furthermore, no abnormal blood chemistry values
were reported.
DISCUSSION
In the present clinical study, we tested the pharmacokinetics,
safety and tolerability of SMEOF#3, a new micro-emulsifying
formulation for oral administration of paclitaxel in combination
with CsA.
The apparent bioavailability of paclitaxel after oral administra-
tion of SMEOF#3 coadministered with CsA was estimated at 40%
(19–83%) and was comparable to the apparent bioavailability of
orally administered Taxol
s. These data were in line with studies
that showed that the apparent bioavailability of orally adminis-
tered Taxol
s in combination with CsA was approximately 47%
(Huizing et al, 1997; Meerum Terwogt et al, 1999).
The term bioavailability, however, should be interpreted with
caution due to the nonlinear pharmacokinetics of i.v. paclitaxel
caused by the presence of CrEL (van Tellingen et al, 1999).
Entrapment of paclitaxel in CrEL micelles in the central
compartment causes a more than proportional increase in plasma
paclitaxel concentrations with increasing doses. Studies in mice
showed that these higher total drug levels in plasma did not result
in higher drug levels in tissues (Sparreboom et al, 1996). Previous
studies showed that CrEL is not absorbed after oral administration.
This pseudo-nonlinearity of i.v. paclitaxel has two important
implications for the pharmacology of oral paclitaxel. Firstly, the
oral bioavailability of paclitaxel, calculated by comparing the AUC
values after oral and i.v. administration, will be underestimated as
the affinity of paclitaxel for the plasma compartment is increased
after i.v. administration due to the presence of CrEL in the central
circulation. Secondly, the pseudo-nonlinearity of i.v. paclitaxel
implies that after oral administration, when CrEL is not present,
plasma levels of paclitaxel represent a higher fraction of free drug,
which will result in enhancement of the availability of paclitaxel for
the (tumour) tissues (van Tellingen et al, 1999). Consequently,
threshold values for the paclitaxel concentration established for i.v.
paclitaxel (Gianni et al, 1995; Huizing et al, 1997) cannot be used
for oral administration of paclitaxel.
The pharmacokinetic parameters of CsA after coadministration
with oral SMEOF#3 and orally administered Taxol
s were
comparable. Furthermore, pharmacokinetic parameters of CsA
were in line with those obtained before (Malingre ´ et al, 2001a–e).
It has been demonstrated that 10mgkg
 1 CsA was sufficient for
maximal enhancement of paclitaxel bioavailability (Malingre ´ et al,
2001a–e). In combination, these facts suggest that a dose of 700mg
CsA as used in this study was sufficient.
Remarkably, the Tmax of paclitaxel after oral administration of
the SMEOF#3 formulation was lower compared to oral Taxol
s.I t
was previously described by us that CrEL limits the absorption rate
of paclitaxel due to encapsulation in CrEL micelles. As the
concentration of CrEL in the gastrointestinal tract decreases with
time due to distribution, breakdown and elimination of CrEL,
more unbound paclitaxel becomes available for absorption in the
systemic circulation with time and consequently the absorption
rate increases (de Jonge et al, 2005). The lower Tmax after oral
SMEOF#3 is probably due to the ability of the SMEOF#3
formulation to remain stable in the gastrointestinal tract avoiding
precipitation of paclitaxel leading to a major fraction of paclitaxel
in solution, which is available for absorption. However, in the case
of oral paclitaxel administered as Taxol
s, probably a significant
amount of paclitaxel precipitates due to quick diffusion and
resorption of ethanol and the precipitated fraction of paclitaxel is
slowly re-dissolved in the gastrointestinal fluids before being
absorbed. Furthermore, a lower amount of ethanol was adminis-
tered after SMEOF#3 160mg compared to the orally applied i.v.
paclitaxel (Taxol
s) formulation 160mg; the amount of adminis-
tered ethanol was approximately 3.3g and 10.6g after SMEOF#3
and the orally applied i.v. paclitaxel (Taxol
s) formulation,
respectively.
An extensive pharmacokinetic analysis demonstrated an in-
crease in the systemic exposure to paclitaxel and a prolonged time
of a paclitaxel concentration above a pharmacological relevant
level with increasing doses of SMEOF#3 (data not shown).
In summary, we demonstrated that the novel SMEOF#3
formulation was well tolerated after oral administration at the
given dose of 160mg when coadministered with CsA, without
induction of relevant gastrointestinal or haematological toxicity.
Regarding the nearly uneventful oral administration of the
160mg dose together with the relatively low AUC0 N after CsA
coadministration, we suggest that new studies should be initiated
with this novel SMEOF#3 formulation to explore once daily
administration of paclitaxel at higher dose levels in order to
increase systemic exposure and to prolong exposure at therapeutic
levels.
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